MedTrace Logo

Antipsychotic to Treat Psychosis Syndrome

NCT02137616 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2014-05-14

No results posted yet for this study

Summary

This study assess the safety and effects of atypical antipsychotics in subjects with psychosis syndrome and psychosis risk syndrome.

Conditions

  • Psychotic Disorders

Interventions

DRUG

risperidone

Risperdal tablets

DRUG

olanzapine

olanzapine tablets

DRUG

Quetiapine

quetiapine tablets

DRUG

Aripiprazole

Aripiprazole tablets

Sponsors & Collaborators

  • Central South University

    lead OTHER

Principal Investigators

  • xiaofeng Guo, Dr · the second xiangya hospitcal

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02137616 on ClinicalTrials.gov